The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and biotechnology sectors.
The ABPI is worried about investment in medicines and moves that could limit patient and doctor treatment choice in the NHS 10-year plan.
AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.
European pharma trade group EFPIA has said that a strategy launched by the EU to bolster the region's standing in life sciences is a "step forward."
Dizal gets US approval for an oral therapy for EGFR exon 20-mutated NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant.
Editor's Picks
